检索结果-南通市图书馆

World Journal of Gastroenterology 2014年第29期20卷 9732-9743页

作者： Alfonso De Stefano chiara carlomagno Department of Clinical Medicine and Surgery University of Naples Federico Ⅱ

Systematic analysis of the epidermal growth factor receptor(EGFR)pathway revealed that biomarkers could be used to predict the response to and outcome of antiEGFR therapies in patients affected by metastatic colorectal *** have conducted a review on the most recent findings and advances on this *** this aim,we searched the PubMed database for articles devoted to predictive and prognostic biomarkers for patients administered cetuximab-and panitumumab-based *** we review the state of the art and the controversies about the molecular factors known to be predictors of the efficacy of anti-EGFR therapy,namely,KRAS,BRAF,NRAS,PI3KCA and PTEN,and we discuss their prognostic value in colorectal cancer patients.

关键词： KRAS Anti-epidermal growth factor receptor Metastatic colorectal cancer Biomarkers

Digital Ischemia in Patients with Solid Tumors: a Case Report and Review of the Literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2011年第2期2卷 281-284页

作者： Lucia Raimondo chiara Alessandra Cella Roberto Moretto Elide Matano chiara carlomagno Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica Universita Federico II

Digital ischemia is a rare paraneoplastic phenomenon associated with various malignancies, especially adenocarcinomas. We reported a case of digital ischemia onset during treatment with capecitabine + oxaliplatin, letrozole and epoetinbeta in a 75-year old woman with colon and breast cancer and a secondary hepatic lesion. A literature review disclosed 68 cases of solid neoplasms associated with digital ischemia. The proposed mechanisms of such clinical manifestations are various: vasospasm due to sympathetic hyperactivity, arteritis induced by tumour antigen-antibody complexes deposition or as consequence of immune deregulation, blood hyperviscosity, hypercoagulability or peripheral thrombosis. In the present case, clinical and laboratory evaluations failed to reveal evidence of thrombosis, arteritis, inherited or acquired hypercoagulable state and we postulated the peripheral vasospasm and the sympathetic activity (possibly due to chemotherapy drugs) as potential causes of the digital ischemia.

关键词： Breast Cancer Colon Cancer Digital Ischemia Paraneoplastic Syndrome

Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy:A retrospective study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Oncology 2021年第5期12卷 355-366页

作者： chiara Maddalena Andrea Ponsiglione Luigi Camera Lidia Santarpia Fabrizio Pasanisi Dario Bruzzese Camilla Panico Giovanni Fiore Simona Camardella Tolomeo Caramia Alessia Farinaro Sabino De Placido chiara carlomagno Department of Clinical Medicine and Surgery University of Naples Federico IINaples 80131Italy Department of Advanced Biomedical Sciences University of Naples Federico IINaples 80131Italy Department of Public Health University of Naples Federico IINaples 80131Italy

BACKGROUND Sarcopenia is a condition characterized by decreased skeletal muscle mass due to physiological ageing or to a concomitant disease such as *** cancer patients,a low lean body mass is suggested to be a negative prognostic factor for survival and for the development of dose-limiting chemotherapy toxicities irrespective of disease *** To evaluate the prognostic role of sarcopenia in patients with metastatic colorectal cancer(mCRC)undergoing first-line *** Our retrospective analysis included 56 mCRC patients who received first-line chemotherapy from 2014 to 2017 at the Medical Oncology Unit of our *** scans were performed before starting chemotherapy and at the first disease *** was assessed using the skeletal mass index=muscle area in cm^(2)/(height in m^(2))calculated at the L3 *** survival and objective response rate were *** were analyzed during the first four cycles of therapy and graded according to Common Terminology Criteria for Adverse Events version 4.0.A loss of skeletal muscle mass≥5%was considered indicative of deterioration in muscle *** Median age was 67 years and 35.7%of patients were≥70 years *** patients(25%)were sarcopenic at baseline computed tomography(CT)scan(7/33 men;7/23 women);5/14 sarcopenic patients were≥70 years *** followup was 26.8 mo(3.8-66.8 mo)and median overall survival was 27.2 mo(95%CI:23.3-37.3).Sarcopenia was not correlated to overall survival(P=0.362),to higher toxicities reported during the first 4 cycles of chemotherapy(P=1.0)or to response to treatment(P=0.221).At the first disease reassessment,a skeletal muscle loss(SML)≥5%was found in 17 patients(30.3%)3 of whom were already sarcopenic at baseline CT scan,while 7 patients became *** was not correlated to overall survival(P=0.961).No statistically significant correlation was found between baseline sarcopenia and age(P=1.0),body m

关键词： Sarcopenia Lean body mass Skeletal muscle mass Metastatic colorectal cancer

Activity and safety of pegylated liposomal doxorubicin,5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma:A phase Ⅱ study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2007年第48期13卷 6553-6557页

作者： Giuseppe Di Lorenzo Antonio Rea chiara carlomagno Stefano Pepe Giovannella Palmieri Roberto Labianca Antonio Chirianni Alfonso De Stefano Vincenzo Esposito Sabino De Placido Vincenzo Montesarchio Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica Università degli Studi Federico Ⅱ Naples Italy Divisione di Oncologia Azienda Ospedaliera Cotugno Naples Italy Oncology Section Ospedali Riuniti Bergamo Italy

AIM: To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase Ⅱ study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA). METHODS: Thirty-one patients with hystologically- confirmed, inoperable HCC, received combination chemotherapy with PLD 25 mg/mq on d 1, 5FU 1200 mg/mq in 48 h continuous infusion, and oral FA 30 mg on d 1 and 2 every 3 wk until disease progression or intolerable toxicity. RESULTS: The median age was 65 years (range 41-82) and 28 patients were hepatitis C virus seropositive (90%). The majority of patients were Child-Pugh Class B (55%). Two patients showed a partial response (PR), and 16 had stable disease (SD). With a median follow-up of 14 mo, the median time to progression of all evaluable patients was 4 mo (95% CI 1.7-7). Median overall survival was 9 mo (95% CI 3-24 mo). After 1 year, 9 of 18 PR/SD patients were alive. Chemotherapy was well tolerated. CONCLUSION: PLD/FU/FA combination seems capable of achieving durable stabilization of HCC. The manageable toxicity supports a role for combination with other anticancer agents.

关键词： Pegylated liposomal doxorubicin 5-fluorouracil Folinic acid Hepatocellular carcinoma

Bevacizumab maintenance in metastatic colorectal cancer: How long?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2014年第11期2卷 717-723页

作者： Alfonso De Stefano Roberto Moretto chiara Alessandra Cella Francesco Jacopo Romano Lucia Raimondo Giovanni Fiore Francesca Di Pietro Stefano Pepe Sabino De Placido chiara carlomagno Department of Clinical Medicine and Surgery School of Medicine University of Naples "Federico II" 80131 Napoli Italy Department of Medicine School of Medicin and Pharmacology University of Salerno 84081 Baronissi (SA)Italy

The management of patients with non-progressive metastatic colorectal cancer after six months of treatment has not yet been codified. The most relevant concerns are the effectiveness of maintenance versus discontinuation, and the tolerability of prolonged treatment. Here we report the case of a 72-year-old man affected by colorectal cancer with lung metastases who achieved a complete response after receiving capecitabine, oxaliplatin and bevacizumab for six months, and bevacizumab alone for six months. Bevacizumab was continued as maintenance regimen for more than three years. It was discontinued because of an arthroplasty. Fifty-eight months after beginning first-line treatment, the patientremains free from relapse. Adverse effects were minimal and easily controlled.

关键词： Metastatic colorectal cancer Bevacizumab Maintenance